Tumor necrosis factor production by peripheral monocytes from head and neck cancer patients

Suppl. XIII, 1991

ABSTRACTS

31

61 COUHARIN RESISTANCE AND LUNG CANCER. M C. Manotti, 1. Poli, R. Quintavalla, i# Pini di Medicina Generale and Centro Emostasi, Ospedale Maggiore, Parma, Italy.

A.G.

Dettori.

5’

Divisione

Recurrence

of venous thradxxis

during

(about

2% in the 3 months treatment

scribe

here three

patients

boestaolism while stologic

diagnosis

Heparin shifted year,

Lou molecular

Another

patient anti-Xa

weight

developed units

These case histories 1)

Counarin

4 years

carcinoma

oral

anticoagulants after

were referred

11.520

units

because of recurrent

was subsequently

and adenocarcinoma

anti-Xa

dosage is unusual

deep venoua thrordsosis).

to our clinic

and in whom a lung cancer

in one case,

at adequate

acute

found.

We dethromThe hi-

in two cases.

signs and symptoms of thrombosis.

heparin,

and did not shou any thrcobotic

rin 4.000

last

in ameliorating

uith

cxnmwnly prescribed

with Acenocouwrol

was epidermoid

was effective

to

uho in the

on therapy

treatment

period

One of these patients

once a day subcutaneously

for

was then about

one

recurrence.

a cerebral

esbolus

after

4 days of treatment

with

Lou molecular

weight hepa-

once a day S.C. suggest the follouing resistance

should alert

considerations: to the presence

of underlying

neoplasm and specifically

of

lung cancer. 2)It

is conceivable of uith

in these

vitamin

K dependent

direct

antithrombin

3) Lou molecular

ueight

cases a persistent

heparin

coagulation activity,

thrtiin

factors, like

thus

generation

notwithstanding

requiring

an antithronbotic

the decrease medication

heparin.

at high dosage may also be effective.

62 FROM MONOCYTES TUMOR NECROSIS FACT&? PRODUCTION BY PERIPHERAL HEAD AND NECK CANCER PATIENTS.Attanasio M.,Gori A.M., Martini F., Boccuzzi S.+, Boscherini G., Giusti B., Pinto S., Gallo O.*, Clinica Medica I e Dilaghi M.*, E.*. Clinica Gallina Otorinolaringoiatrica*. University of Florence. squamous In patients (pts)with advanced head and neck carcinoma (HNSC),evidence of cell-mediated immunity and monocyte of this (M) functional abnormalities has been reported.The aim by LPS activated M study iS to investigate the release of TNF(HNSC). from pts with advanced head and neck squamous carcinomas 6 with oral cavity cancer) Ten male pts (4 with sopraglottic and were grouped and ten controls have been The pts studied. Karnofsky and according to TNM classification of UICC1987 criteria. Pure M were incubated with LPS (10 pg/mL) for 4 hrs at 37'C.TNF-d concentrations in supernatants were determined with a produced specific from pts Stimulated M ELISA (Biokine). signigicantly (p70 or ~70 was 926 ng/lO ng/lO cells respectively. Cur findings show that M from advanced but HNSC patients have an increased capability to produce TNF, TNF production is not relevant in cancer-related clinical state.